AI Trends

Isomorphic Labs Completes $5 Billion Series C Funding Round to Advance AI Drug Discovery Infrastructure

Phoenix TechnologyUpdated Nov 19 09:57

AI summary

Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round, which will be used to advance foundational simulation models, expand its pipeline of drug candidates, and build AI-driven bioengineering infrastructure. A 2024 BCG report said that AI-generated drug molecules have an 80%-90% success rate in Phase I clinical trials, compared with the historical industry average of 40%-65%. Soochow Securities believes that the AI drug discovery technology stack is shifting from standalone algorithmic tools to a multimodal technology matrix.

Why read this

AI score 60

Drawing on Isomorphic Labs' financing plans and BCG clinical data, the report outlines how AI drug discovery is expanding from algorithmic tools into a multimodal technology matrix.

Topics

Tags

Body · AI translation

AI Significantly Boosts the Success Rate of New Drug R&D as the AI Drug Discovery Value Chain Continues to Expand Download the Cailian Press App for Exclusive Early Access November 19, 2026, 08:05:00, from Beijing Updated November 19, 2026, 08:20:23

AI drug discovery company Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round. Isomorphic Labs plans to use the funding to continue advancing the development of foundation simulation models, expand its portfolio of internal and collaborative drug candidates, and build global AI-driven bioengineering infrastructure.

Soochow Securities said that, according to a 2024 BCG report, AI-generated drug molecules achieved an 80%-90% success rate in Phase I clinical trials, far above the historical industry average of 40%-65%. AI is expected to significantly improve the overall success rate of new drug development. The AI drug discovery technology stack has undergone a fundamental transformation from standalone algorithmic tools into a multimodal technology matrix.

According to the Cailian Press Theme Database, among the relevant listed companies:

Sino Biological produces and sells more than 74,000 types of off-the-shelf products in total, including over 9,000 recombinant proteins, more than 14,000 antibodies, over 50,000 genes, and a range of high-performance serum-free culture media, covering multiple areas of life sciences research.

“Special notice: The above content (including any videos, images, or audio) was uploaded and published by users of Dafeng Hao, a self-media platform operated by Phoenix New Media. This platform only provides information storage services.

Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”

Source

Phoenix Technology